Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of GDC-9545 + palbociclib versus letrozole + palbociclib in ER-positive, HER2-negative advanced or metastatic breast cancer
CTR20211218Phase 3Active
- Sponsor
- Roche
- Start
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of giredestrant in breast cancer, sponsored by Roche. Started Sep 2021; status: active.
02
Drugs
giredestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on CTR20211218.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20211218.